Brokerages Set Selecta Biosciences Inc (SELB) Target Price at $35.00

Shares of Selecta Biosciences Inc (NASDAQ:SELB) have received a consensus recommendation of “Buy” from the six research firms that are presently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $35.00.

A number of analysts recently weighed in on the stock. ValuEngine raised shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Canaccord Genuity upped their target price on shares of Selecta Biosciences from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, May 23rd. Zacks Investment Research raised shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, May 15th. Mizuho reissued a “buy” rating and issued a $30.00 target price on shares of Selecta Biosciences in a research note on Wednesday, April 11th. Finally, BidaskClub raised shares of Selecta Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 15th.

Selecta Biosciences traded down $0.23, reaching $12.23, on Wednesday, according to MarketBeat. The company’s stock had a trading volume of 192,500 shares, compared to its average volume of 271,670. The stock has a market cap of $275.13 million, a P/E ratio of -3.82 and a beta of -3.60. Selecta Biosciences has a 52 week low of $7.95 and a 52 week high of $24.02. The company has a quick ratio of 7.20, a current ratio of 7.20 and a debt-to-equity ratio of 0.51.



Selecta Biosciences (NASDAQ:SELB) last posted its earnings results on Wednesday, May 9th. The company reported ($0.71) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.11). Selecta Biosciences had a negative net margin of 31,556.04% and a negative return on equity of 111.69%.

Institutional investors have recently modified their holdings of the business. DRW Securities LLC bought a new stake in Selecta Biosciences during the first quarter worth about $122,000. Two Sigma Advisers LP bought a new stake in Selecta Biosciences during the fourth quarter worth about $143,000. Keybank National Association OH bought a new stake in Selecta Biosciences during the fourth quarter worth about $143,000. SG Americas Securities LLC bought a new stake in Selecta Biosciences during the fourth quarter worth about $145,000. Finally, Wells Fargo & Company MN grew its stake in Selecta Biosciences by 125.8% during the fourth quarter. Wells Fargo & Company MN now owns 23,491 shares of the company’s stock worth $230,000 after buying an additional 13,086 shares during the last quarter. 45.73% of the stock is currently owned by hedge funds and other institutional investors.

About Selecta Biosciences

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply